Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

This study tests whether a drug called durvalumab (an immunotherapy) can help prevent small cell lung cancer from coming back after patients in China have completed chemotherapy combined with radiation therapy. Small cell lung cancer (SCLC) is an aggressive type of lung cancer. **You may be eligible if...** - You are 18 or older - You have been diagnosed with limited-stage small cell lung cancer (stages I–III) - Your cancer did not get worse during your chemotherapy and radiation treatment - You completed your chemoradiation within an acceptable timeframe - You are in reasonably good physical health **You may NOT be eligible if...** - Your cancer progressed during or after chemoradiation - You have received prior immunotherapy - You have severe autoimmune disease or conditions that require immune-suppressing medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.